Actively Recruiting
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-12
51
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed/refractory indolent T/NK-cell lymphomas. Patients will be treated with Linperlisib or Duvelisib, with an expected overall response rate of 60% for PI3K inhibitor treatment.
CONDITIONS
Official Title
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with relapsed or refractory indolent T/NK-cell lymphomas
- Adults aged 18 years or older
- Able to take oral PI3K inhibitor treatment
- No prior use of PI3K inhibitors
- Tumors that have not progressed after treatment over a specific period, including complete response, partial response, or stable disease
You will not qualify if you...
- Previous use of any PI3K inhibitors
- Conditions that interfere with drug absorption or compliance, such as dysphagia or chronic gastrointestinal diseases
- Unable to stop medications that prolong QT interval during the study
- Active infections requiring treatment (viral, bacterial, fungal)
- Hepatitis B or C infection or active hepatitis
- History of immunodeficiency, HIV, organ or stem cell transplantation
- Autologous stem cell transplant within 90 days before study treatment
- Severe or uncontrolled cardiovascular disease
- Serious diseases that threaten safety or study completion (e.g., uncontrolled hypertension, diabetes, thyroid disease)
- Pregnant or breastfeeding women, or positive pregnancy test at baseline
- Other malignancies diagnosed or treated within past 5 years
- Any condition deemed unsuitable by the investigator for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
S
Shuhua Yi, Doctor
CONTACT
L
Lugui Qiu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here